NCT01673659View on ClinicalTrials.gov

A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR)

PHASE3CompletedINTERVENTIONAL
Enrollment

1,220

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Seasonal Allergic Rhinitis
Interventions
DRUG

Mometasone furoate

DRUG

Nasonex Nasal Spray

DRUG

Placebo nasal spray

Trial Locations (1)

Unknown

San Antonio

Sponsors

Lead Sponsor

Padagis LLC
All Listed Sponsors
lead

Padagis LLC

INDUSTRY

NCT01673659 - A Safety and Bioequivalence of a Mometasone Nasal Spray, 50 mcg/Actuation Compared With Nasonex® Nasal Spray 50 mcg/Actuation in the Relief of the Symptoms of Seasonal Allergic Rhinitis (SAR) | Biotech Hunter | Biotech Hunter